Clinical Trial

Treatment for Low Risk HIV-1 Infection

Study Description

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Islatravir

Islatravir administered orally in capsule form once monthly for 24 weeks

Drug - Placebo

Placebo for islatravir administered orally in capsule form once monthly for 24 weeks

Additional Information

Official Study Title

A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection

Clinical Trial ID

NCT04003103

ParticipAid ID

aOYprd